STLX-2012
Lower Risk-MDS and CMML
Key Facts
About Stelexis Therapeutics
Stelexis Therapeutics is a private, clinical-stage biotech company pioneering first-in-class therapies for hematological malignancies with significant unmet need. The company's strategy centers on rapidly generating proof-of-concept for its lead assets, Eganelisib and STLX-2012, as monotherapies and in combinations. Led by a seasoned management team with deep hematology-oncology expertise, Stelexis is advancing a focused pipeline designed to induce remissions and prevent relapse in difficult-to-treat blood cancers.
View full company profileAbout Stelexis Therapeutics
Stelexis Therapeutics is a private, clinical-stage biotech company pioneering first-in-class therapies for hematological malignancies with significant unmet need. The company's strategy centers on rapidly generating proof-of-concept for its lead assets, Eganelisib and STLX-2012, as monotherapies and in combinations. Led by a seasoned management team with deep hematology-oncology expertise, Stelexis is advancing a focused pipeline designed to induce remissions and prevent relapse in difficult-to-treat blood cancers.
View full company profile